BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SAR439459 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SAR439459\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04643002-3356@assetmemo.bio
DTSTAMP:20261121T005832Z
DTSTART;VALUE=DATE:20270913
DTEND;VALUE=DATE:20270914
SUMMARY:SAR439459: Phase 1/2 readout est. (NCT04643002)
DESCRIPTION:SAR439459\, phase 1/2\, Multiple Myeloma.\nStudy: Isatuximab in
  Combination With Novel Agents in RRMM - Master Protocol\nEstimated primar
 y completion: 13 September 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/sar439459#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT04643002
URL:https://assetmemo.bio/drug/sar439459#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
